豆浆不煮熟煮透，所含的胰蛋白酶抑制物未被破坏，不仅豆浆难以消化，还会引起恶心、呕吐和腹泻。
Cook soy milk is not cooked, contained in trypsin inhibitors have not been destroyed, not only difficult to digest soy milk, but also cause nausea, vomiting and diarrhea.
目的研究基质金属蛋白酶- 9 (MMP - 9)和基质金属蛋白酶抑制物- 1 (TIMP - 1)在早孕期蜕膜和绒毛中的表达特点。
Objective to study the expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) proteins in the decidua and villi of the early pregnancy.
研究者还发现2型纤维蛋白溶酶原激活因子抑制物(PAI2)(一种丝氨酸蛋白酶抑制物)抑制结核杆菌感染的巨噬细胞内的膜联蛋白- 1的蛋白水解作用。
The researchers also found that plasminogen activator inhibitor type 2 (PAI2), a serine-protease inhibitor, inhibited proteolytic truncation of annexin-1 in macrophages infected with M. tuberculosis.
基本的单链多肽，通过与酶的活性位点紧密结合形成复合物，抑制大多数的丝氨酸蛋白酶。
Basic single-chain polypeptide that inhibits numerous serine proteases by binding to the active site of the enzyme, forming tight complexes.
向细胞裂解液中加入蛋白酶抑制剂后可以保护细胞提取物中的靶蛋白。
The addition of protease inhibitors to the cell lysis buffer AIDS in the preservation of target proteins in the cell extract.
金属蛋白酶抑制剂，含有它们的药物组合物和其药物用途，其制备方法和中间体。
Metalloproteinase inhibitors, pharmaceutical compositions containing the same and their pharmaceutical USES, and methods and intermediates useful for their preparation.
金属蛋白酶抑制剂，含有它们的药物组合物和其药物用途，其制备方法和中间体。
Inhibitors of metalloproteinase, pharmaceutical compositions containing them, their pharmaceutical application and methods and intermediate compounds for their preparation.
综述了有机硼酸类化合物作为酶抑制剂的研究进展，重点介绍了近年来发现的丝氨酸蛋白酶抑制剂、蛋白酶体抑制剂和精氨酸酶抑制剂。
The recent progress of boronic acid derivatives used as enzyme inhibitors is reviewed focused on the serine protease inhibitors, proteasome inhibitors, and arginase inhibitors.
目的研究基质金属蛋白酶-2（MMP-2）及其抑制物组织基质金属蛋白酶抑制剂-2（TIMP-2）在大肠癌进展中的作用及其临床意义。
Purpose To understand the relationship between the expression of MMP-2, TIMP-2 and the clinical significance in human colorectal carcinoma.
基质金属蛋白酶的组织特异性抑制物是一组多功能基因家族，它们能特异性地抑制基质金属蛋白酶。
The tissue inhibitor of metalloproteinases (TIMPs) are a large family of multi-functional genes, and they specifically inhibit MMPs.
本发明还涉及含有结构式(I)的天冬氨酸蛋白酶抑制剂的药物组合物。
The present invention is also directed to pharmaceutical compositions comprising the aspartic protease inhibitors of Structural Formula (I).
本发明公开了新的具有HCV蛋白酶抑制活性的大环化合物以及制备这些化合物的方法。
The present invention discloses novel macrocyclic compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds.
AT通过与参与血液凝固的蛋白酶形成复合物，抑制凝结剂的作用。
At inhibits coagulant action by forming a complex with the protease involved in blood coagulation.
这样的组合物及方法应用蛋白酶抑制剂和一种肺表面活性物质混合物。
Such compositions and methods employ protease inhibitors and a lung surfactant mixture.
应用一氧化氮和基质蛋白酶的抑制剂明显降低肝窦内皮细胞的损伤，表明一氧化氮和基质蛋白酶在缺血-再灌注损伤中是重要的介导物。
The inhibitor for NO or for MMPs significantly reduced the LSEC IRI, suggesting that NO and MMPs are important mediators in the LSEC IRI.
应用一氧化氮和基质蛋白酶的抑制剂明显降低肝窦内皮细胞的损伤，表明一氧化氮和基质蛋白酶在缺血-再灌注损伤中是重要的介导物。
The inhibitor for NO or for MMPs significantly reduced the LSEC IRI, suggesting that NO and MMPs are important mediators in the LSEC IRI.
应用推荐